Agree that the low separation between Oxy and placebo is somewhat surprising. Not sure what the dosing for Oxy was in this trial. I imagine the Oxy and 797 are fairly close, which is quite encouraging.
Hopefully ARRY's fantastic biz development team partners this in the next 6-9 months. Seems like an opportunity for someone with bigger pockets to explore in Phase 3 given the amount of data they have on this drug.
It looks like Virtex had a P38 program until 2007 and then they shelved it. They too saw QT issues in their trials but nothing significant. They also reported some liver issues but those too weren't significant. The P38 MAPK inhibitors in general appear to have safety issues so the conclusion appears to be that developing them for inflammation will be costly. Given that Virtex was unable to find a partner I doubt ARRY will find one but perhaps they've got a better compound that the Virtex one.
Market Data 
Markets 
AI
